F. R. Livingston

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.3K citations · Full text

Mendelian Disorder, Genetics, Ivacaftor Combination Regimen +2

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 116 citations · Full text

Medicine, Hypertonic Saline, Dornase Alfa +1

Hypoxic and hypercapnic ventilatory responses in Prader-Willi syndrome

Raanan Arens, David Gozal, K. J. Omlin et al. · Journal of Applied Physiology · 1994 · 109 citations

Obesity, Sleep Disorders, Sleep +14

Hypercapnic Arousal Responses in Prader-Willi Syndrome

F. R. Livingston, Raanan Arens, Sandra L. Bailey et al. · CHEST Journal · 1995 · 72 citations

Neuropsychology, Psychiatry, Behavioral Neuroscience +8